SYN Synthetic Biologics, Inc. Commo

0.59
-0.031  -5%
Previous Close 0.62
Open 0.61
Price To book 28.33
Market Cap 72.16M
Shares 121,894,000
Volume 1,288,604
Short Ratio 17.04
Av. Daily Volume 1,145,910

SEC filingsSee all SEC filings

  1. 8-K - Current report 17844086
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814978
  3. 8-K - Current report 17814177
  4. 8-K - Current report 17813892
  5. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17659822

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 2 trial commenced October 2015. 12 week data met endpoints. Phase 2b/3 trial planned for 2017.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 2b topline data released January 5, 2017. Primary endpoint met. Phase 3 trial to be initiated 1H 2018.
SYN-004
C. difficile Infection

Latest News

  1. Can The Uptrend Continue for Synthetic Biologics (SYN)?
  2. Today's Research Reports on Stocks to Watch: Quantum Corporation and Synthetic Biologics
  3. Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
  4. Edited Transcript of SYN earnings conference call or presentation 4-May-17 8:30pm GMT
  5. SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
  6. Synthetic Biologics reports 1Q loss
  7. Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results
  8. Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017
  9. Synthetic Biologics to Present at the 29th Annual ROTH Conference
  10. Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results
  11. Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
  12. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
  13. Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
  14. Synthetic Biologics C. Difficile Drug Trial Succeeds
  15. Synthetic Biologics' C. difficile mid-stage study meets main goal
  16. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  17. Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference
  18. Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
  19. Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences

SEC Filings

  1. 8-K - Current report 17844086
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814978
  3. 8-K - Current report 17814177
  4. 8-K - Current report 17813892
  5. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17659822
  6. 8-K - Current report 17658893
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17610062
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 17607363
  9. 8-K - Current report 17598481
  10. 8-K - Current report 17534769